Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5137 Target Snapshot

Metabotropic glutamate receptor 2 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,251Compounds
402Assays
0Approved Drugs
3,400.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Metabotropic glutamate receptor 2 shows late clinical disease relevance led by schizophrenia. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q14416. Start with schizophrenia, then reuse UniProt Q14416 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with schizophrenia, then reuse UniProt Q14416 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
schizophrenia

Metabotropic glutamate receptor 2 shows late clinical disease relevance led by schizophrenia. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with schizophrenia because it currently carries late clinical support. Linked drugs include JNJ-40411813, POMAGLUMETAD METHIONIL ANHYDROUS. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Metabotropic glutamate receptor 2 as ChEMBL target CHEMBL5137, mapped to UniProt Q14416. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Metabotropic glutamate receptor 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5137
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q14416
Metabotropic glutamate receptor 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Metabotropic glutamate receptor 2 is the right protein anchor across sources, using UniProt Q14416 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why schizophrenia is currently framed as late clinical support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameMetabotropic glutamate receptor 2
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ14416
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMetabotropic glutamate receptor 2
UniProt AccessionQ14416
Component TypeProtein
Sequence Length872 aa

Metabotropic glutamate receptor 2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Metabotropic glutamate receptor 2, mapped to UniProt Q14416. Sequence length is 872 aa.

Mapped IDQ14416
Review nameMetabotropic glutamate receptor 2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Metabotropic glutamate receptor 2 shows late clinical disease relevance led by schizophrenia. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
schizophrenia
2 linked drugs · 2 direct · 2 efficacy
Linked drugJNJ-40411813
Linked drugPOMAGLUMETAD METHIONIL ANHYDROUS
Clinical signal Phase II
major depressive disorder
2 linked drugs · 2 direct · 2 efficacy
Linked drugDECOGLURANT
Linked drugJNJ-40411813
Clinical signal Phase II
depressive disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugDECOGLURANT
Clinical signal Phase II
Seizure
1 linked drug · 1 direct · 1 efficacy
Linked drugJNJ-40411813
Clinical signal Phase I
bipolar disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugLY2979165
Clinical signal Phase I
methamphetamine dependence
1 linked drug · 1 direct · 1 efficacy
Linked drugPOMAGLUMETAD METHIONIL ANHYDROUS
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with schizophrenia because it currently carries late clinical support. Linked drugs include JNJ-40411813, POMAGLUMETAD METHIONIL ANHYDROUS. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseschizophrenia
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Phase III
6
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC501,799.0
KI258.0
EC501,298.0
KD45.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL218710 10.05 EC50 0.089 Preclinical
CHEMBL2381640 9.8 EC50 0.16 Preclinical
CHEMBL3955188 9.72 Ki 0.19 Preclinical
CHEMBL5950884 9.7 EC50 0.2 Preclinical
CHEMBL5405921 9.49 Ki 0.32 Preclinical
CHEMBL3883435 9.4 EC50 0.4 Preclinical
CHEMBL3884532 9.4 EC50 0.4 Preclinical
CHEMBL6037536 9.4 EC50 0.4 Preclinical
CHEMBL3945590 9.34 Ki 0.46 Preclinical
CHEMBL3884187 9.3 EC50 0.5 Preclinical
Distribution

pChEMBL Value Distribution

101
5.0
166
5.5
361
6.0
511
6.5
584
7.0
710
7.5
380
8.0
71
8.5
19
9.0
3
9.5
pChEMBL
Assay Landscape

Assay Landscape

402
Total Assays
1,094
Tested Compounds
3
Assay Types
Functional — 212 assays, 1,094 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 163 709 6.8
assay format 39 351 7.3
cell membrane format 5 32 7.6
single protein format 5 2 6.2
Binding — 181 assays, 1,043 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 92 705 7.1
single protein format 80 134 6.6
assay format 7 164 7.3
cell membrane format 2 40 8.2
Unassigned — 9 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 9 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine